APIIC's Brian Doty says key starting materials are where domestic generic supply efforts must focus, and continuous flow chemistry makes the business case.
Brian Doty, Ph.D.
Advertisement
Brian Doty, Ph.D., is vice president of R&D and programs at the API Innovation Center.
Articles by Brian Doty, Ph.D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How CMS’ Final Negotiation Rule Treats New Drug Formulations
2
When Drug Pricing Collides With Politics
3
The AI Efficiency Trap: Why Faster Tasks Alone Won’t Transform Life Sciences
4
Big Three Distributors Lean on Specialty for Profit Growth
5